Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Roche gains EU PRIME status for Spinraza rival

Oral treatment joins Novartis' gene therapy challenger

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

- PMLiVE

Novartis withdraws EU filing for canakinumab

Further setback for cardiovascular blockbuster potential

- PMLiVE

Is China ready for a pharmaceutical gold rush?

Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?

We’ve moved!

Blue Latitude Health has moved office to a new location in Barbican, Central London, following a year of substantial growth.

Blue Latitude Health

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

NICE appraisal fees to be introduced despite opposition

Concessions made for small companies

- PMLiVE

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours

- PMLiVE

AZ still sees route to approval for Imfinzi in MYSTIC trial

New analysis shows opportunity in NSCLC

- PMLiVE

AstraZeneca’s oncology renaissance

Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...

New editor adds microscopic attention to detail at Porterhouse Medical

The Porterhouse Medical Group is delighted to welcome Isabel Thomas to our scientific services team in Reading.Joining us as an associate editor, Isabel will be working closely alongside Stephanie, senior editor, to boost...

Porterhouse Medical Group

- PMLiVE

Brexit contributes to surge in generic drug prices

Calls for government to protect pharmacies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links